On August 4, the Biden administration declared monkeypox a public health emergency. The announcement comes on the heels of the World Health Organization’s declaration in July that monkeypox was a public health emergency of international concern. This means that monkeypox poses a global public health risk through international spread, which requires a coordinated international response.
In the United States, prior to the announcement of the Biden administration, an increasing number of municipalities and even many states – California, Illinois and New York – declared monkey pox a public health emergency.
a public health announcement It allows the Secretary of Health and Human Services (HHS) to take certain actions in response to a threat of disease or crisis of some kind to the public health. Public health emergencies are not only declared in the event of outbreaks of infectious diseases such as Covid-19 and capricorn. For example, in October 2017, President Trump declared the “opioid crisis” a “public health emergency.”
Importantly, declaring a public health emergency unlocks resources dedicated to an actual (or emerging) public health crisis. In the case of monkeypox, the federal government can now significantly expand vaccine production and availability, expand testing capacity, and make testing more convenient. The announcement also facilitates coordination between federal, state and local authorities, especially with regard to obtaining testing and treatment in conjunction with a preventive awareness campaign for members of at-risk communities, which aims to limit the spread of the virus.
Moreover, advertising Allow The HHS Secretary conducts and supports investigations into the cause, treatment, or prevention of a disease or crisis, as well as support for advanced research and development and vital monitoring needed to address the problem at hand. Finally, the CDC provides access to the Infectious Disease Rapid Response Reserve Fund to prevent, prepare for, or respond to infectious disease emergencies.
According to the Centers for Disease Control and Prevention (CDC), more than 26,000 cases of monkeypox have been reported in 87 countries. With more than 6,500 confirmed cases, the United States makes up 25% of confirmed infections worldwide.
So far, no deaths from monkeypox have been reported in the United States, but in the most recent global outbreak, which began in May of this year, at least 6 deaths occurred outside the United States, moreover, between 3% and 3% were transmitted 13% of confirmed cases are hospitalized. Most hospitalizations are dedicated to pain management. Patients often experience debilitating pain from the rash caused by the virus. Skin lesions can occur anywhere on the body. Common systemic features Prior to the onset of the rash, they included fever (62%), lethargy (41%), myalgia (31%), headache (27%), and swollen lymph nodes (56%).
Besides pain management, reasons cited for hospitalization included pharyngitis limiting oral intake, encephalitis, eye lesions, acute kidney injury, and myocarditis.
Men who have sex with men are currently at a higher risk, but anyone can get monkeypox. In fact, an increasing number of women and children have been shown to be infected with the virus.
What is definitively known is monkeypox margins Through direct contact with body fluids or sores on the body of a person with monkeypox, or through direct contact with items, such as clothing and linens, that have touched the body fluids or sores. It may also spread through respiratory droplets when people have close face-to-face contact.
The US has increased testing capacity to 80,000 per week. However, the current demand for testing exceeds the current capacity in the United States in terms of testing supplies.
In 2019, the Food and Drug Administration (FDA) approved a vaccine called Jynneos for adults 18 years of age or older who are at high risk of developing monkeypox or smallpox. Jynneos is the only FDA-approved monkeypox vaccine in the United States, given in two doses 28 days apart. On July 15, 2022, HHS Strategic Preparedness and Response announced that it had ordered an additional 2.5 million doses of Jynneos to bolster monkeypox preparedness, which would increase the supply available to the federal government to more than 6.9 million doses by mid-year. 2023.
So far, HHS . has made 786,000 doses available of Jynneos for state and local authorities. But lawmakers and local communities have criticized the pace of the response. Because of supply shortages, the Food and Drug Administration is now considering dividing doses of Genos into fifths.
CDC Director Dr. Walensky has admitted this The demand for the vaccine is outstripping the supply. An additional 11.1 million doses are stocked in Denmark with the manufacturer Bavarian Nordic. However, these doses must be “filled and terminated” before they can be administered, which would require additional funding from Congress.
The United States also has more than 100 million doses of an older generation smallpox vaccine, called ACAM2000, which is potentially effective against monkeypox. But, ACAM2000 can have serious side effects and is not recommended for those with compromised immune systems, such as HIV patients, pregnant women, and people with autoimmune disorders.
In terms of other treatments, the United States has 1.7 million cycles of antiviral therapy in its Strategic National Stockpile. Some doctors use tecovirimat to treat monkeypox patients. But, this drug has only been approved by the US Food and Drug Administration for smallpox.
It is hoped that declaring a public health emergency will lead to an intensification of testing and treatment for monkeypox, as well as public health messages about preventing the spread of the disease, particularly in at-risk communities.